- Syros Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
Mar 27, 2024, 7:30 AM EDT - Syros Announces Completion of Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in SELECT-MDS-1 Phase 3 Trial
Mar 25, 2024, 7:00 AM EDT - Syros to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 27, 2024
Mar 20, 2024, 7:00 AM EDT - Syros to Participate in TD Cowen 44th Annual Health Care Conference
Feb 27, 2024, 7:00 AM EST - Syros Highlights Anticipated 2024 Milestones to Deliver on the Value of Tamibarotene
Jan 8, 2024, 7:00 AM EST - Syros Announces Pricing of $45.0 million Underwritten Offering of Common Stock and Pre-Funded Warrants
Dec 19, 2023, 7:27 AM EST - Syros Announces Encouraging Initial Data from Randomized SELECT-AML-1 Phase 2 Clinical Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine
Dec 6, 2023, 7:00 AM EST - Syros to Participate in Upcoming Investor Conferences
Nov 21, 2023, 7:30 AM EST - Syros Reports Third Quarter 2023 Financial Results and Provides a Corporate Update
Nov 14, 2023, 7:30 AM EST - Syros to Report Third Quarter 2023 Financial Results on Tuesday, November 14, 2023
Nov 7, 2023, 7:30 AM EST